New active substance reprieve for Genzyme's Aubagio good news for Biogen
This article was originally published in Scrip
Sanofi/Genzyme will be relieved to hear that the European Medicines Agency's Committee for Medicinal Product for Human Use has, after all, decided to give MS drug Aubagio (teriflunomide) new active substance status. The news not only secures data exclusivity, staving off generic competition, for Aubagio, but could also be a good sign for Biogen Idec. The biotech company is wrangling with the EMA over whether its own MS drug Tecfidera (dimethyl fumarat) qualifies for data exclusivity.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.